Mark Kozloff to Pyrazoles
This is a "connection" page, showing publications Mark Kozloff has written about Pyrazoles.
Connection Strength
0.187
-
Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer. Br J Cancer. 2018 11; 119(10):1208-1214.
Score: 0.149
-
TGFß receptor inhibitor galunisertib is linked to inflammation- and remodeling-related proteins in patients with pancreatic cancer. Cancer Chemother Pharmacol. 2019 05; 83(5):975-991.
Score: 0.038